Loading…

Browse All Grants

20,252 grants found

Filters
Reset

Showing 19,54119,560 of 20,252 grants

Completed NON-SBIR/STTR RPGS
Pro-Drug Enolase Inhibitors in Precision Oncology
NATIONAL CANCER INSTITUTE University of Tx Md Anderson Can Ctr United States 2021 – 2026

ABSTRACT.Genomic deletions of major tumor suppressor genes are frequent events in cancer yet presently remain therapeutically unactionable for the purpose of precision oncology.Our...

$3.3M
USD
Completed NON-SBIR/STTR RPGS
Synthetic rocaglates as promising therapeutic agents for aggressive hematological malignancies
NATIONAL CANCER INSTITUTE Roswell Park Cancer Institute Corp United States 2021 – 2023

Project Summary/Abstract Despite the significant advances in therapy development, a large proportion of hematological malignancies, especially the aggressive types remain incurable...

$2.47M
USD
Completed NON-SBIR/STTR RPGS
Pro-Drug Enolase Inhibitors in Precision Oncology
NATIONAL CANCER INSTITUTE University of Tx Md Anderson Can Ctr United States 2021 – 2026

ABSTRACT. Genomic deletions of major tumor suppressor genes are frequent events in cancer yet presently remain therapeutically unactionable for the purpose of precision oncology. O...

$3.23M
USD
Completed NON-SBIR/STTR RPGS
Synthetic rocaglates as promising therapeutic agents for aggressive hematological malignancies
NATIONAL CANCER INSTITUTE Roswell Park Cancer Institute Corp United States 2021 – 2024

Project Summary/Abstract Despite the significant advances in therapy development, a large proportion of hematological malignancies, especially the aggressive types remain incurable...

$1.68M
USD
Completed NON-SBIR/STTR RPGS
Pro-Drug Enolase Inhibitors in Precision Oncology
NATIONAL CANCER INSTITUTE University of Tx Md Anderson Can Ctr United States 2021 – 2026

ABSTRACT. Genomic deletions of major tumor suppressor genes are frequent events in cancer yet presently remain therapeutically unactionable for the purpose of precision oncology. O...

$3.23M
USD
Completed NON-SBIR/STTR RPGS
Pro-Drug Enolase Inhibitors in Precision Oncology
NATIONAL CANCER INSTITUTE University of Tx Md Anderson Can Ctr United States 2021 – 2026

ABSTRACT. Genomic deletions of major tumor suppressor genes are frequent events in cancer yet presently remain therapeutically unactionable for the purpose of precision oncology. O...

$3.13M
USD
Completed NON-SBIR/STTR RPGS
Mechanisms of differentiation blockade in CSF3R-mutant AML
NATIONAL CANCER INSTITUTE Oregon Health & Science University United States 2021 – 2026

PROJECT SUMMARY Acute Myeloid Leukemia (AML) is a lethal blood cancer, with a 5-year survival rate of only 25%. One driver of especially poor prognosis in AML is mutation of Colony...

$3.8M
USD
Completed NON-SBIR/STTR RPGS
Increasing nerve-sparing radical prostatectomy rates using intraoperative nonlinear microscopy
NATIONAL CANCER INSTITUTE Massachusetts Institute of Technology United States 2021 – 2026

Prostate cancer is the most common cancer in the US male population, with an estimated 160,000 new cases in 2018.Treatment with radical prostatectomy (RP), complete surgical excisi...

$4.66M
USD
Completed NON-SBIR/STTR RPGS
Comprehensive molecular characterization of endometrial cancer, etiologic heterogeneity, and racial disparities
NATIONAL CANCER INSTITUTE Brigham and Women'S Hospital United States 2021 – 2026

ABSTRACT Endometrial cancer (EC) is the most common gynecologic cancer in the US.Incidence is increasing, especially for aggressive, understudied tumors that confer poor prognosis...

$11.25M
USD
Completed NON-SBIR/STTR RPGS
Overcoming immune checkpoint inhibition with therapeutic plasma exchange and radiotherapy in melanoma
NATIONAL CANCER INSTITUTE Mayo Clinic Rochester United States 2021 – 2023

ABSTRACT PD-1-directed immune checkpoint inhibitors (ICI) have significantly improved survival in metastatic melanoma compared to traditional chemotherapy. Unfortunately, less than...

$2.02M
USD
Completed NON-SBIR/STTR RPGS
Patient-derived organoids reveal rectal cancers develop radiosensitivity
NATIONAL CANCER INSTITUTE Sloan-Kettering Inst Can Research United States 2021 – 2024

The Fearon and Vogelstein multistep cancer progression model of colon cancer defines key genetic changes associated with progression from normal colorectal tissue to early/late ade...

$2.43M
USD
Completed NON-SBIR/STTR RPGS
Mechanisms of differentiation blockade in CSF3R-mutant AML
NATIONAL CANCER INSTITUTE Oregon Health & Science University United States 2021 – 2026

PROJECT SUMMARY Acute Myeloid Leukemia (AML) is a lethal blood cancer, with a 5-year survival rate of only 25%. One driver of especially poor prognosis in AML is mutation of Colony...

$3.8M
USD
Completed NON-SBIR/STTR RPGS
Increasing nerve-sparing radical prostatectomy rates using intraoperative nonlinear microscopy
NATIONAL CANCER INSTITUTE Massachusetts Institute of Technology United States 2021 – 2026

Prostate cancer is the most common cancer in the US male population, with an estimated 160,000 new cases in 2018. Treatment with radical prostatectomy (RP), complete surgical excis...

$4.78M
USD
Completed NON-SBIR/STTR RPGS
Comprehensive molecular characterization of endometrial cancer, etiologic heterogeneity, and racial disparities
NATIONAL CANCER INSTITUTE Brigham and Women'S Hospital United States 2021 – 2026

ABSTRACT Endometrial cancer (EC) is the most common gynecologic cancer in the US. Incidence is increasing, especially for aggressive, understudied tumors that confer poor prognosis...

$10.47M
USD
Completed NON-SBIR/STTR RPGS
Overcoming immune checkpoint inhibition with therapeutic plasma exchange and radiotherapy in melanoma
NATIONAL CANCER INSTITUTE Mayo Clinic Rochester United States 2021 – 2024

ABSTRACT PD-1-directed immune checkpoint inhibitors (ICI) have significantly improved survival in metastatic melanoma compared to traditional chemotherapy. Unfortunately, less than...

$1.61M
USD
Completed NON-SBIR/STTR RPGS
Increasing nerve-sparing radical prostatectomy rates using intraoperative nonlinear microscopy
NATIONAL CANCER INSTITUTE Massachusetts Institute of Technology United States 2021 – 2026

Prostate cancer is the most common cancer in the US male population, with an estimated 160,000 new cases in 2018. Treatment with radical prostatectomy (RP), complete surgical excis...

$4.64M
USD
Completed NON-SBIR/STTR RPGS
Mechanisms of differentiation blockade in CSF3R-mutant AML
NATIONAL CANCER INSTITUTE Oregon Health & Science University United States 2021 – 2026

PROJECT SUMMARY Acute Myeloid Leukemia (AML) is a lethal blood cancer, with a 5-year survival rate of only 25%. One driver of especially poor prognosis in AML is mutation of Colony...

$3.72M
USD
Completed NON-SBIR/STTR RPGS
Patient-derived organoids reveal rectal cancers develop radiosensitivity
NATIONAL CANCER INSTITUTE Sloan-Kettering Inst Can Research United States 2021 – 2023

The Fearon and Vogelstein multistep cancer progression model of colon cancer defines key genetic changes associated with progression from normal colorectal tissue to early/late ade...

$2.07M
USD
Completed NON-SBIR/STTR RPGS
Increasing nerve-sparing radical prostatectomy rates using intraoperative nonlinear microscopy
NATIONAL CANCER INSTITUTE Massachusetts Institute of Technology United States 2021 – 2026

Prostate cancer is the most common cancer in the US male population, with an estimated 160,000 new cases in 2018. Treatment with radical prostatectomy (RP), complete surgical excis...

$4.63M
USD
Completed NON-SBIR/STTR RPGS
Mechanisms of differentiation blockade in CSF3R-mutant AML
NATIONAL CANCER INSTITUTE Oregon Health & Science University United States 2021 – 2026

PROJECT SUMMARY Acute Myeloid Leukemia (AML) is a lethal blood cancer, with a 5-year survival rate of only 25%. One driver of especially poor prognosis in AML is mutation of Colony...

$3.61M
USD